Mabwell Biotech News and Activities

Mabwell Biotech is a company listed under the stock ticker 2493 HK (CN).

Acquisition, funding and merger involving Mabwell Biotech.

• Mabwell Biotech has just announced a $185 Million fundraising (posted on May 4 2026).
• Mabwell Biotech is now listed under ticker 2493 HK. (posted on April 28 2026).

View the org chart displaying its 13 main executives

Most searched biographies at Mabwell Biotech

• Datao Liu, President
• Xun Gui, Board Member
• Han Li, Vice President

Create your alert
to follow the executive moves at Mabwell Biotech.

Mabwell Biotech has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Mabwell Biotech

• Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting
• FDA Grants Fast Track Designation to 9MW2821 for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
• Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor at ASCO 2024
• Mabwell to Debut Clinical Study Results of 9MW3011 at EHA2024
• Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
• MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
• SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential
• Mabwell to Present ADC Platform IDDC™ and the Latest Study Results of Multiple Novel ADCs at the 14th World ADC London
• Mabwell ranks on the list of 2024 Top 100 Hardcore Technology Enterprises in Shanghai
• Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London
• View more press releases Close

Social media about Mabwell Biotech

• Mabwell Biotech on Wikipedia, Google News & Yahoo Finance
• Mabwell Biotech on LinkedIn, X (Twitter) & YouTube